News

Inovio Shares Surge After FDA Approves First DNA Medicine for Rare Disease

+2

Health

Inovio Shares Surge After FDA Approves First DNA Medicine for Rare Disease

Maya Lindstrom · 2026-10-31T05:20:43.770Z

This approval should make a real difference for patients facing repeated surgeries for that condition.

8 sourcesUpdated Oct 31, 20261 min read

+2

Inovio Shares Surge After FDA Approves First DNA Medicine for Rare Disease — © IJR

Sponsored

On October 30, 2026, the FDA granted accelerated approval to INOVIO Pharmaceuticals' VOCERYQ, previously known as INO-3107, for adults with recurrent respiratory papillomatosis. The DNA medicine is approved with INOVIO's CELLECTRA 5PSP device to reduce the frequency of surgical papilloma excisions. INOVIO describes it as the first FDA-approved DNA medicine. Approval was based on a complete response defined as no surgical intervention required in the 12 months after treatment in the efficacy population. Continued approval may depend on a confirmatory study verifying clinical benefit. INOVIO must submit a draft protocol by the end of 2026 and finalize it by mid-2027. The company expects VOCERYQ available to order and ship in about 60 days. The stock closed the regular session down 21.95% at $0.6024. RTTNews reported it rose 241.93% to $2.0598 in after-hours trading. Seeking Alpha headlines cited 280% and 300% surge figures for the same move. No other factual dispute appears in the record.

Sponsored

In this story:

Sponsored

How it spread

Broke pluang.com · Oct 30, 2:01 PM ETRight +4hCenter +4h8 sources +10h on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

How each side headlines it

Left· 0 sources

No left coverage yet — a bubble gap.

Center· 2 sources

“Inovio Pharmaceuticals Gets FDA Accelerated Approval for VOCERYQ”

MarketScreener · Oct 30, 2026

Right· 2 sources

“Inovio surges 280% following FDA approval of Voceryq for rare disease (INO:NASDAQ)”

Seeking Alpha · Oct 30, 2026

Coverage

Sponsored

Comments (2)

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Tom Gallagher⚡73d
The delayed launch until 2027 seems far off but the stock surge shows real promise for DNA medicines.
Maya Lindstrom⚡53d
This approval should make a real difference for patients facing repeated surgeries for that condition.

Sponsored

More on this story

Back to News

Health

FDA approves first generic twice-yearly HIV-prevention shot

FDA approved the first generic of twice-yearly HIV-prevention shot lenacapavir at about $40 a year for 120 resource-limited countries; U.S. brand lists at $28,218.

18 sources

Health

FDA grants uniQure Huntington’s gene therapy priority review

The FDA accepted uniQure’s application for priority review of its experimental Huntington’s disease gene therapy, setting a May 1, 2027, decision target and tentatively planning an advisory committee meeting. The application seeks accelerated approval based on clinical data compared with an external control; acceptance is not approval, and a confirmatory trial is planned.

8 sources

Sponsored

Health

FDA Proposes First Formula Nutrient Update in Decades

The FDA has proposed the first major update to U.S. infant-formula nutrition standards in nearly 30 years, revising requirements for vitamins A and D, iodine and manganese while seeking input on whether to require ingredients such as DHA, ARA and L-carnitine. The proposal also includes labeling changes; the agency said most tested formula samples had low or undetectable chemical contaminants and plans further reviews before issuing a final rule.

22 sources